Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.
In this interview with The Center for Biosimilars®, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses some of the issues that clinics face when prescribing biosimilars, including pricing, payer policy, and inventory challenges.
Dave says switching to biosimilars helped Texas Oncology reduce save 20% on a small group of drugs for which biosimilars were available. He mentions a pilot program at Texas Oncology where they used biosimilars for 3 drugs for 3 months. Across the board, the health system was able to save $4 million monthly.
Asked about the incentives for manufacturers to develop more oncology biosimilars amid increasing competition, Dave says that companies may have to find another way to compete rather than developing a new biosimilar for a reference product with 3 or more competitors.
However, he argues that pricing a product significantly lower in a market that already has a lot of competition is the best way to compete in such a market.
Clinics are challenged when they have to stock multiple biosimilars for the same reference product, and payers’ preferences do not always align with the clinic’s interests, he says. Although giving a patient the wrong biosimilar should not produce any clinical differences, on an administrative level, it can cause billing issues and result in additional costs for the practice. Dave says that, to help prevent these issues from occurring, clinics should be the ones to determine which biosimilars to use.
Dave reevaluates his pharmacy practices regularly because drug prices and biosimilar utilization change on a quarterly basis. These reevaluations will occur during pharmacy and therapeutics committee meetings, and those discussions are needed to figure out what can be done to improve biosimilar utilization, and consequently, cost savings.
Finally, Dave discusses the importance of clinics regularly reevaluating the prices of the biosimilars they’re using, because a biosimilar that enters the market as the most cost-efficient option may not stay that way forever. He stresses that clinics need to ensure that as prices change that they are continuing the use the most cost-effective option to prevent increasing the cost of care.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.